Feasibility and Benefit of Molecularly-Informed Enrollment Into Early Phase Clinical Trials for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.142_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐cell Lymphoma

American Journal of Hematology
Hematology
2019English

A Phase Iia Study Evaluating the Safety and Tolerability of Umbralisib and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy